New Funding in Hand, Neutra Casts Eye Towards Technology in Vertical Integration Drive

SUGAR LAND, TX / ACCESSWIRE / February 19, 2020 / Neutra Corp. (NTRR) continues its efforts towards vertical integration, this time examining the potential of integrating technology into its hemp-based CBD enterprise. The company believes the time is right to add a technological dimension to its operation and that such an addition could lead to greater future growth and expansion opportunities.

“This is a natural progression of our ongoing vertical integration push,” said Sydney Jim, Neutra’s CEO. “Last year, we enjoyed success with the VIVIS acquisition that gave us a retail presence. We expect similar results in our efforts to acquire land and facilities for hemp cultivation. Adding a technology component to our growing mix would make us a stronger, more competitive company in control of the entire process from the field, to the lab to the retail store.”

Earlier this month, Neutra announced it had received a fresh round of private equity funding. These new funds could help the company partner with an existing CBD-related technology company or acquire one. A CBD-related technology company is typically involved in improving CBD delivery methods, such as boosting concentrations and increasing absorption rates.

CBD is a natural, multi-purpose hemp compound believed to offer a wide range of medical benefits. Users report relief from anxiety, lessening of the effects of seizures, slowing of neurodegenerative disorders, pain relief, and alleviation of certain cancer treatment side effects. Hemp-extracted CBD consumers also don’t face the dangers of addiction, in contrast to opioid users.

The Hemp Business Journal has forecasted that by 2022, sales of hemp-derived products will reach $22 billion by 2022. Last year, that same market posted sales of $390 million.

NOTICE REGARDING FORWARD LOOKING STATEMENT

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

Neutra Corp. (NTRR) is an early-stage research and development company that’s bringing modern healthy living solutions to a multi-billion dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture-one where consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving Hemp-based CBD market, in which we intend to participate.

CONTACT:

Sydney Jim
888-433-4033
info@neutrainc.com

SOURCE: Neutra Corp

View source version on accesswire.com:
https://www.accesswire.com/577008/New-Funding-in-Hand-Neutra-Casts-Eye-Towards-Technology-in-Vertical-Integration-Drive

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

2 hours ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

2 hours ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

2 hours ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

2 hours ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

2 hours ago